Project Grant DP2EB039061
Award Date 8/15/25
Completion Date 7/31/28
Dollars Obligated $1.4M
Funding Federal Agency
Awarding Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
- This $438,900 Project Grant was awarded by the National Institute of Biomedical Imaging and Bioengineering (NIBIB) under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286). The grant funds research to develop a "three-cell (T-NK-macrophage) immunotherapy system" using chimeric antigen receptor (CAR) and synthetic cytokine receptor (SCR) technologies. The primary goal is to engineer the three immune cell types to function...
- The Leland Stanford Junior University was awarded a $1,108,391.72 Project Grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) with a project period from January 1, 2025 to December 31, 2027. The grant supports research to define the most therapeutically relevant CAR T cell subsets in patients with large B cell lymphoma (LBCL) and overcome immune suppression mechanisms of resistance to CAR T cell therapy. Key research activities include following...
- The National Institutes of Health, National Cancer Institute awarded a $140,433 Project Grant to The Leland Stanford Junior University under the Cancer Research Manpower (CFDA 93.398) program. The award will be used to generate CD19.28Z chimeric antigen receptor (CAR) T cells in vivo using a Programmable Antibody-mediated Cellular Knock-in of T cells (PACK-IT) system. The goals are to optimize the PACK-IT system, compare the resulting PACK-IT CAR-T cells to conventionally manufactured CAR-T...
- This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) to The Leland Stanford Junior University totals $170,376.00 and is focused on developing a rapid, label-free, and cost-effective technique for Chimeric Antigen Receptor (CAR) T cell quantification in patient blood using Surface Enhanced Raman Spectroscopy (SERS) and Machine Learning (ML). The key products and services to be delivered under this award include: Optimizing a SERS...
- The National Institutes of Health (NIH) awarded a $1,413,277 Project Grant under the Trans-NIH Research Support program (CFDA 93.310) to The Leland Stanford Junior University (Stanford University) to develop and apply two key technical innovations: 1) CRISPR-ALL, an arbitrarily combinatorial genetic perturbation platform in primary human cells, and 2) the combinatorial construction of new "non-evolved" human genes from existing functional human protein domains, initially focusing on...
- This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) supports the development of "Next Generation Platforms for Interrogating TCR Specificity" at The Leland Stanford Junior University. The $368,294 award spanning 9/1/2025 to 8/31/2028 will optimize two complementary methods to identify, detect, and target peptide-MHC tumor antigens. This includes improving a yeast peptide-MHC display platform to discover new tumor...
- This federal Project Grant award of $640,522 from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) to The Leland Stanford Junior University supports research to elucidate how microbial microproteins modulate macrophage function, a critical coordinator of tumor immune response. The project aims to carry out high-throughput screens of thousands of microbial macromolecules to identify those that directly modulate macrophages, with the goal of enhancing cancer immunotherapy...
- This Project Grant award from the Trans-NIH Research Support program, CFDA #93.310, provides $1,350,770 to The Leland Stanford Junior University to develop a novel class of synthetic RNA-based receptors to enhance the targeting precision of mRNA-mediated adoptive cell therapies. The project aims to create a modular, programmable receptor system that can convert ligand-induced dimerization events into the expression of desired output proteins, enabling improved specificity for ablating target...
- This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research by the University of California, San Francisco (UCSF) to genetically engineer myeloid cells, including macrophages and dendritic cells, for the treatment of solid tumors. The $0.00 award, with a project period from August 1, 2025 to July 31, 2028, aims to apply advanced genetic engineering tools to reprogram myeloid cells and enhance their tumoricidal activities and resistance to...
- This federal Project Grant award, valued at $469,381.00, was provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to The Leland Stanford Junior University. The award period runs from April 15, 2025 to April 14, 2027. The purpose of this grant is to fund research focused on "ENGINEERING CYTOTOXIC LYMPHOCYTES TO INFILTRATE OVARIAN CANCER TUMORS VIA METABOLITE-SENSING RECEPTORS". This advanced biomedical research aims to transform...